Yaokai Chen to Humans
This is a "connection" page, showing publications Yaokai Chen has written about Humans.
Connection Strength
0.061
-
How COVID-19 Patient Narratives Concerning Reinfection Mirror Their Mental Health: A Case Series. Psychiatr Danub. 2021; 33(1):114-119.
Score: 0.007
-
Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment. Front Immunol. 2020; 11:570063.
Score: 0.007
-
Potential therapeutic options for coronavirus disease 2019: using knowledge of past outbreaks to guide future treatment. Chin Med J (Engl). 2020 06 05; 133(11):1350-1352.
Score: 0.007
-
Six weeks into the 2019 coronavirus disease outbreak: it is time to consider strategies to impede the emergence of new zoonotic infections. Chin Med J (Engl). 2020 May 05; 133(9):1118-1120.
Score: 0.007
-
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. Chin Med J (Engl). 2020 May 05; 133(9):1132-1134.
Score: 0.007
-
Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial. Chin Med J (Engl). 2020 May 05; 133(9):1080-1086.
Score: 0.007
-
SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic Variants. Microbiol Spectr. 2021 09 03; 9(1):e0026121.
Score: 0.002
-
The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. Signal Transduct Target Ther. 2021 03 08; 6(1):113.
Score: 0.002
-
Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020 Dec; 9(1):1269-1274.
Score: 0.002
-
Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection. Virology. 2021 01 15; 553:131-134.
Score: 0.002
-
The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther. 2020 10 06; 5(1):219.
Score: 0.002
-
Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduct Target Ther. 2020 09 02; 5(1):180.
Score: 0.002
-
Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol Infect. 2020 Nov; 26(11):1556.e1-1556.e6.
Score: 0.002
-
A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019. J Infect Dis. 2020 06 29; 222(2):189-193.
Score: 0.002
-
Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 06; 26(6):845-848.
Score: 0.002
-
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020 06; 17(6):647-649.
Score: 0.002